ULTRAVIST 240 Drug Patent Profile

When do Ultravist 240 patents expire, and what generic alternatives are available?

Ultravist 240 is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in ULTRAVIST 240 is iopromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.

Summary for ULTRAVIST 240

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	11
Patent Applications:	2,584
DailyMed Link:	ULTRAVIST 240 at DailyMed

Recent Clinical Trials for ULTRAVIST 240

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bayer	Phase 4
Guerbet/Liebel-Flarsheim	Phase 4
Duke Clinical Research Institute	Phase 4

See all ULTRAVIST 240 clinical trials

Pharmacology for ULTRAVIST 240

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for ULTRAVIST 240

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	ULTRAVIST 240	iopromide	INJECTABLE;INJECTION	020220-003	May 10, 1995		DISCN	Yes	No

Expired US Patents for ULTRAVIST 240

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	ULTRAVIST 240	iopromide	INJECTABLE;INJECTION	020220-003	May 10, 1995

International Patents for ULTRAVIST 240

See the table below for patents covering ULTRAVIST 240 around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2909439
Yugoslavia	61780
Spain	491254
South Africa	8001350
Australia	529565
Finland	800696
Spain	489337

ULTRAVIST 240 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of ULTRAVIST 240

Introduction to ULTRAVIST 240

ULTRAVIST 240, a brand of the iodinated contrast agent iopromide, is widely used in medical imaging procedures. It is manufactured by Bayer, which acquired the rights through its merger with Schering AG. Here, we will delve into the market dynamics and financial trajectory of ULTRAVIST 240.

Market Overview

Global Demand and Export Trends

ULTRAVIST, including its various concentrations such as ULTRAVIST 240, has seen significant global demand. From March 2023 to February 2024, there were 394 shipments of ULTRAVIST worldwide, involving 45 exporters and 66 buyers. This period marked a 4% growth rate compared to the preceding twelve months[1].

Key Exporters and Importers

Germany leads the world in ULTRAVIST exports, followed by India and Turkey. The primary importers include Argentina, India, and Colombia. This distribution highlights the global reach and demand for ULTRAVIST 240 and other concentrations[1].

Product Indications and Usage

Medical Applications

ULTRAVIST 240 mgI/mL is indicated for various medical imaging procedures, including peripheral venography, contrast-enhanced computed tomography (CECT) of the head and body, and other intra-arterial and intravenous procedures. Its use is critical in providing clear contrast enhancement, enabling accurate diagnoses in conditions such as vascular disorders and cerebral arteriography[3].

Pharmacokinetics and Safety

The drug's pharmacokinetics show rapid distribution and excretion, primarily through the renal route. It is dialyzable and has a short half-life, making it safe for use in a wide range of patients, although dose adjustments may be necessary for those with renal impairment[3].

Financial Performance

Sales and Revenue

Bayer's pharmaceutical division, which includes the radiology business segment, has seen steady growth. In the second quarter of 2024, sales of prescription medicines rose by 4.5% on a currency- and portfolio-adjusted basis, with significant contributions from the radiology segment driven by higher volumes and prices for CT Fluid Delivery and ULTRAVIST™[4].

Market Impact and Growth Drivers

The growth in ULTRAVIST sales can be attributed to several factors, including increased demand for diagnostic imaging procedures and the product's reliability and safety profile. The radiology business has been a key contributor to Bayer's overall pharmaceutical sales, with ULTRAVIST being a significant component of this segment[4].

Competitive Landscape

Market Competitors

ULTRAVIST competes with other iodinated contrast agents such as iohexol and iopamidol. Clinical trials have shown that ULTRAVIST has comparable or superior visualization ratings and diagnostic accuracy to its competitors, which helps maintain its market position[3].

Regulatory and Safety Considerations

Historically, there have been recalls due to safety concerns, such as the presence of particulate matter and crystallization in ULTRAVIST 370 mgI/mL. However, these issues have been addressed, and the product continues to be used safely under strict quality control measures[2].

Market Trends and Future Outlook

Global Health Trends

The increasing need for diagnostic imaging due to rising healthcare standards and an aging population drives the demand for contrast agents like ULTRAVIST 240. Advances in medical technology and the expansion of healthcare services in emerging markets are expected to further boost demand.

Economic Factors

Currency fluctuations and market conditions can impact the financial performance of ULTRAVIST sales. However, Bayer's diversified portfolio and strong market presence help mitigate these risks. The company's continued investment in research and development ensures that ULTRAVIST remains a competitive product in the market[4].

Best Practices in Use

Clinical Guidelines

The use of ULTRAVIST 240 must adhere to best practices in the clinical setting, including proper dosing, route of administration, and safety protocols. Pharmacists and healthcare professionals play a crucial role in ensuring the safe and effective use of iodinated contrast media[5].

Key Takeaways

• Global Demand: ULTRAVIST 240 has a strong global demand, with significant exports from Germany, India, and Turkey.
• Medical Applications: It is used in various medical imaging procedures, including peripheral venography and CECT.
• Financial Performance: The product contributes to Bayer's growing pharmaceutical sales, particularly in the radiology segment.
• Competitive Landscape: ULTRAVIST competes with other iodinated contrast agents and maintains its market position through its safety and efficacy.
• Future Outlook: The demand is expected to grow due to increasing healthcare needs and advances in medical technology.

FAQs

What is ULTRAVIST 240 used for?

ULTRAVIST 240 is used for medical imaging procedures such as peripheral venography, contrast-enhanced computed tomography (CECT) of the head and body, and other intra-arterial and intravenous procedures.

Who are the main exporters of ULTRAVIST?

The main exporters of ULTRAVIST are Germany, India, and Turkey.

What are the key safety considerations for ULTRAVIST 240?

Key safety considerations include the potential for renal impairment and the need for dose adjustments. Historically, there have been recalls due to particulate matter and crystallization, but these issues have been addressed.

How does ULTRAVIST 240 compare to other iodinated contrast agents?

ULTRAVIST 240 has comparable or superior visualization ratings and diagnostic accuracy to other iodinated contrast agents like iohexol and iopamidol.

What drives the demand for ULTRAVIST 240?

The demand is driven by the increasing need for diagnostic imaging due to rising healthcare standards and an aging population, as well as advances in medical technology.

Sources

1. Volza.com: Ultravist Exports from World - Volza.com
2. Biospace.com: Schering AG Voluntarily Recalls Ultravist(R) Injection 370 mgI/ml
3. FDA.gov: Ultravist - accessdata.fda.gov
4. Bayer.com: Modest performance in challenging agricultural market ... - Bayer
5. ASHP.org: Best Practices in the Use of Iodinated Contrast Media in the Clinical Setting: What the Pharmacist Needs to Know